SMILES string
[s]1c(nc(c1)CSCCN\C(=C\[N+](=O)[O-])\NC)CN(C)C
InChI
1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
InChI key
SGXXNSQHWDMGGP-IZZDOVSWSA-N
grade
pharmaceutical primary standard
API family
nizatidine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Nizatidine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
M Apostu et al.
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 111(2), 530-534 (2007-11-07)
Phosphotungstic acid forms salt type ionic association complexes with a large number of medicinal drugs that contain cation forming proton acceptor moieties. Ranitidine, nizatidine and famotidine complexes with phosphotungstic acid were synthesized and subsequently characterized by their melting point, water
Yin-Xia Chang et al.
The Analyst, 136(20), 4168-4173 (2011-08-23)
A validated, simple, and sensitive fluorescence quenching method for the determination of ranitidine, nizatidine, and cimetidine in tablets and biological fluids is presented. This is the first single fluorescence method reported for the analysis of all three H(2) antagonists. The
Juan V Esplugues et al.
Medicina clinica, 127(20), 790-795 (2007-01-03)
The significant inhibitory capacity of gastric acid secretion of PPIs makes them the drugs of choice for treating acid-related diseases. The considerable prevalence of these diseases and the need for maintaining the administration of the drug during considerably long periods
Sebastian Haag et al.
Clinical therapeutics, 32(4), 678-690 (2010-05-04)
Systematic assessments of the onset of symptom relief in the treatment of gastroesophageal reflux disease (GERD) are lacking. This work evaluated the time interval until complete symptom relief from heartburn (including both daytime and nighttime heartburn) and acid regurgitation in
Sjogren's syndrome: promising, new treatment options besides nizatidine.
Shailendra Kapoor
Modern rheumatology, 19(1), 100-101 (2008-10-09)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持